Gene News and Research

Latest Gene News and Research

Researchers identify gene mutation for that is essential for correct protein-processing in cells

A Jackson Laboratory research team led by Professor Patsy Nishina, Ph.D., has identified a mutation in a gene that's essential for correct protein-processing in cells. Defects in protein folding are associated with a variety of abnormalities and diseases.

10 Jan 2011

AFQ056 drug improves symptoms in Fragile X patients: Study

The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise according to a new study published in the January issue of Science Translational Medicine.

9 Jan 2011

Secret behind viruses making covert attacks unravelled: Study

Some viruses use a form of disguise to avoid being detected by the body’s immune system. Now researchers from Melbourne have found out the secret behind the Trojan-horse like phenomenon. Gabrielle Belz and her colleagues at Parkville’s Walter and Eliza Hall Institute in collaboration with researchers from the University of Cambridge found the key viral gene that was responsible for the phenomenon called K3. The study appeared in the current issue of the Journal of Immunology.

9 Jan 2011

Gigantism gene inherited by hundreds: Study

A gene that predicted gigantism in humans was identified in the DNA of the 18th-century man known as the Irish Giant, who was more than 7 feet 7 inches tall. Copies of the same mutation have been found in patients today who suffer from excessive growth, and scientists have concluded they all inherited the gene from a common ancestor.

9 Jan 2011

Impulse Monitoring announces acquisition of Great Lakes Intraoperative Monitoring

Impulse Monitoring, Inc. (IMI), a leading provider of intraoperative neurophysiologic monitoring (IONM) services to hospitals, today announced that it has acquired the assets of Great Lakes Intraoperative Monitoring, LP (GLIM), a subsidiary of Williamsville, NY-based Archer Medical Diagnostic Testing, Inc.

7 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Targeted Genetics acquires Biocontrol

Targeted Genetics Corporation, today announced the completion of the acquisition of Biocontrol Limited.

7 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Spirogen, Genentech enter multi-year ADC research collaboration and license agreement

Spirogen Ltd. a leading oncology-focused company developing DNA sequence targeted agents, announced a multi-year research collaboration and license agreement with Genentech, a member of the Roche Group.

7 Jan 2011

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., and RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

Researchers identify genetic mutation responsible for acromegaly disease

An international research team, spearheaded by scientists from the London School of Medicine and Dentistry, has identified the genetic mutation responsible for a disease known as "gigantism" or acromegaly.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

New research: NFKBIA gene loss induces glioblastoma development

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Urine tests could detect Obsessive Compulsive Disorder

Australian researchers have found a novel and easy way to detect a common and debilitating anxiety disorder called the Obsessive Compulsive Disorder or OCD. Scientists at the Centenary Institute in Sydney discovered a gene responsible for a rare kidney disorder is also behind OCD. This may make detecting OCD easier through a simple urine test. This test could also identify babies with risk of early-onset OCD. OCD affects up to 3 per cent of all Australians and in its worst cases can be completely debilitating, causing people to have to stay at home. OCD sufferers feel intense anxiety and are compelled to practice rituals - such as hand washing or arranging objects.

6 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

Gene News and Research

Latest Gene News and Research

Researchers identify gene mutation for that is essential for correct protein-processing in cells

AFQ056 drug improves symptoms in Fragile X patients: Study

Secret behind viruses making covert attacks unravelled: Study

Gigantism gene inherited by hundreds: Study

Impulse Monitoring announces acquisition of Great Lakes Intraoperative Monitoring

MMRF awards $3 million under 2010 Biotech Investment Awards program

Targeted Genetics acquires Biocontrol

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Spirogen, Genentech enter multi-year ADC research collaboration and license agreement

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Researchers identify genetic mutation responsible for acromegaly disease

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

New research: NFKBIA gene loss induces glioblastoma development

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Urine tests could detect Obsessive Compulsive Disorder

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging